Pegaspargase (Polyethylene Glycol-L-Asparaginase)
- 1 June 1996
- journal article
- new drug-profile
- Published by Springer Nature in Clinical Immunotherapeutics
- Vol. 5 (6) , 492-496
- https://doi.org/10.1007/bf03259345
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemiaCancer, 1995
- Comparative pharmacokinetic studies of three asparaginase preparations.Journal of Clinical Oncology, 1993
- L-Asparaginase and PEG Asparaginase— Past, Present, and FutureLeukemia & Lymphoma, 1993
- Asparaginase RevisitedLeukemia & Lymphoma, 1993
- High efficacy of monomethoxypolyethylene glycolconjugated l-asparaginase (PEG2-ASP) in two patients with hematological malignanciesLeukemia Research, 1991
- L-Asparaginase: Clinical, Biochemical, Pharmacological, and Immunological StudiesAnnals of Internal Medicine, 1971
- L-Asparaginase and Human Malignant DiseaseNature, 1971
- Clinical results of treatment with E. coli L-asparaginase in adults with leukemia, lymphoma, and solid tumorsCancer, 1970
- L-Asparaginase Therapy for Leukemia and Other Malignant NeoplasmsJAMA, 1967
- Toxic and antineoplastic effects of l-asparaginase: Study of mice with lymphoma and normal monkeys and report on a child with leukemiaCancer, 1966